Fig. 2: Median invasive disease-free survival (iDFS) and overall survival (OS). | Nature Communications

Fig. 2: Median invasive disease-free survival (iDFS) and overall survival (OS).

From: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

Fig. 2: Median invasive disease-free survival (iDFS) and overall survival (OS).

iDFS (A) and OS (B) stratified by treatment arm. iDFS (C) and OS (D) stratified by the presence or absence of circulating tumor DNA (ctDNA) at landmark in patients enrolled in Arms A, B, and C combined. Blue line: Arm A (nivolumab); Red line: arm B (capecitabine); Green line: Arm C (combination of nivolumab and capecitabine). Source data are provided as a source data file.

Back to article page